+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sexually Transmitted Diseases Testing Market by Disease Type and Location of Testing: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 159 Pages
  • December 2021
  • Region: Global
  • Allied Market Research
  • ID: 5548427
The STD testing market accounted for $91,445.93 million in 2020, and is expected to reach $1,50,445.01 million by 2030, registering a CAGR of 5.1% from 2021 to 2030. Sexually transmitted diseases (STDs) are considered as one of the most critical health challenges globally. Chlamydia, gonorrhea, and herpes simplex virus are some of the highly prevalent STDs. The STD testing market has witnessed significant growth in the past decade with increasing prevalence of STDs. With high prevalence, coverage of STD diagnosis facilities has also majorly increased in the developed countries. However, in developing regions, STD diagnosis facilities are still inadequate to provide wider coverage to the population with STDs. Inadequate facilities for STD diagnosis are the major concern in developing regions.



STDs have witnessed substantial growth in their prevalence and incidents in the past decade. With increasing prevalence, respective countries across the world are focusing on implementation of national screening programs to expand the coverage of STD diagnosis. Moreover, reimbursement policies have also been favorable for STD services. These factors are significantly driving the growth of the global STD testing market. On the other hand, limited access to STD diagnosis in developing regions is expected to restrain the market growth.

The STD testing market is segmented on the basis of disease type, location of testing, and region. By disease type, it is divided into chlamydia, syphilis, gonorrhea, herpes simplex virus, human papillomavirus (HPV), human immunodeficiency virus testing, and others. By location of testing, the market is bifurcated into laboratory testing, and point of care (PoC) testing. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global STD Testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the products and end users of STD Testing used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS


By Disease Type

  • Chlamydia
  • Gonorrhea
  • Herpes simplex virus
  • Syphilis
  • Human papillomavirus (HPV)
  • Other diseases (human immunodeficiency virus (HIV), chancroid, trichomoniasis, and hepatitis B)

By Location of Testing

  • Laboratory testing
  • Point of care (POC) testing
  • By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • Italy
  • France
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle East and Africa

KEY MARKET PLAYERS

  • Abbott laboratories
  • Becton Dickinson Company
  • BioMérieux, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Diasorin Molecular LLC
  • Hologic, Inc.
  • Orasure Technologies, Inc.
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
Frequently Asked Questions about the STD Testing Market

What is the estimated value of the STD Testing Market?

The STD Testing Market was estimated to be valued at $91445.93 million in 2020.

What is the growth rate of the STD Testing Market?

The growth rate of the STD Testing Market is 5.1%, with an estimated value of $150445.01 million by 2030.

What is the forecasted size of the STD Testing Market?

The STD Testing Market is estimated to be worth $150445.01 million by 2030.

Who are the key companies in the STD Testing Market?

Key companies in the STD Testing Market include Abbott laboratories, Becton Dickinson Company, BioMérieux Inc., Bio, Rad Laboratories Inc., Danaher Corporation, Diasorin Molecular LLC, Hologic IncOrasure Technologies Inc. and Thermo Fisher Scientific Inc..

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits to Stakeholders
1.3. Key market segments
1.3.1. LIST OF KEY PLAYERS PROFILED IN THE REPORT
1.4. Research methodology
1.4.1. SECONDARY RESEARCH
1.4.2. PRIMARY RESEARCH
1.4.3. ANALYST TOOLS AND MODELS
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. TOP INVESTMENT POCKETS
3.2.2. TOP WINNING STRATEGIES
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. DRIVERS
3.5.1.1. High prevalence and rise in incidences of STD across the world
3.5.1.2. Implementation of national screening programs
3.5.1.3. Supporting reimbursement for STDs testing
3.5.2. RESTRAINTS
3.5.2.1. Social stigma associated with patients visiting specialized STD clinics
3.5.2.2. Huge proportion of patients infected with STDs in remote areas
3.5.2.3. Stringent regulatory abidance requirements for the participants of STD market
3.5.3. OPPORTUNITIES
3.5.3.1. Decrease in number of visits to government clinics
3.5.3.2. National screening programs across the globe
3.5.3.3. Niche opportunities for technology and POC test providers in an emerging economy
3.5.4. IMPACT ANALYSIS
3.6. COVID-19 impact analysis on the STD testing market
CHAPTER 4: STD TESTING MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. MARKET SIZE AND FORECAST (VOLUME AND VALUE)
4.2. Chlamydia
4.2.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
4.2.2. MARKET SIZE AND FORECAST (VOLUME AND VALUE)
4.3. Gonorrhea
4.3.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
4.3.2. MARKET SIZE AND FORECAST (VOLUME AND VALUE)
4.4. Herpes simplex virus
4.4.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
4.4.2. MARKET SIZE AND FORECAST (VOLUME AND VALUE)
4.5. Syphilis
4.5.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
4.5.2. MARKET SIZE AND FORECAST (VOLUME AND VALUE)
4.6. Human papillomavirus (HPV)
4.6.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
4.6.2. MARKET SIZE AND FORECAST (VOLUME AND VALUE)
4.7. Other diseases
4.7.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
4.7.2. MARKET SIZE AND FORECAST (VOLUME AND VALUE)
CHAPTER 5: STD TESTING MARKET, BY LOCATION OF TESTING
5.1. Overview
5.1.1. MARKET SIZE AND FORECAST (VOLUME AND VALUE)
5.2. Laboratory testing
5.2.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
5.2.2. MARKET SIZE AND FORECAST (VOLUME AND VALUE)
5.3. Point of care (POC) testing
5.3.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
5.3.2. MARKET SIZE AND FORECAST (VOLUME AND VALUE)
CHAPTER 6: STD TESTING MARKET, BY REGION
6.1. Overview
6.1.1. MARKET SIZE AND FORECAST
6.2. North America
6.2.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
6.2.2. MARKET SIZE AND FORECAST, BY COUNTRY
6.2.2.1. U.S.
6.2.2.1.1. Market analysis.
6.2.2.2. Canada
6.2.2.2.1. Market analysis.
6.2.2.3. Mexico
6.2.2.3.1. Market analysis.
6.2.3. NORTH AMERICA MARKET SIZE AND FORECAST, BY DISEASE TYPE
6.2.4. NORTH AMERICA MARKET SIZE AND FORECAST, BY LOCATION OF TESTING
6.3. Europe
6.3.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
6.3.2. MARKET SIZE AND FORECAST, BY COUNTRY
6.3.2.1. Germany
6.3.2.1.1. Market analysis.
6.3.2.2. France
6.3.2.2.1. Market analysis.
6.3.2.3. UK
6.3.2.3.1. Market analysis.
6.3.2.4. Italy
6.3.2.4.1. Market analysis.
6.3.2.5. Rest of Europe
6.3.2.5.1. Market analysis.
6.3.3. EUROPE MARKET SIZE AND FORECAST, BY DISEASE TYPE
6.3.4. EUROPE MARKET SIZE AND FORECAST, BY LOCATION OF TESTING
6.4. Asia-Pacific
6.4.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
6.4.2. MARKET SIZE AND FORECAST, BY COUNTRY
6.4.2.1. Japan
6.4.2.1.1. Market analysis.
6.4.2.2. China
6.4.2.2.1. Market analysis.
6.4.2.3. India
6.4.2.3.1. Market analysis.
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Market analysis.
6.4.3. ASIA-PACIFIC MARKET SIZE AND FORECAST, BY DISEASE TYPE
6.4.4. ASIA-PACIFIC MARKET SIZE AND FORECAST, BY LOCATION OF TESTING
6.5. LAMEA
6.5.1. KEY MARKET TRENDS, GROWTH FACTORS, AND OPPORTUNITIES
6.5.2. MARKET SIZE AND FORECAST, BY COUNTRY
6.5.3. LATIN AMERICA
6.5.3.1.1. Market analysis.
6.5.4. MIDDLE EAST AND AFRICA
6.5.4.1.1. Market analysis.
6.5.5. LAMEA MARKET SIZE AND FORECAST, BY DISEASE TYPE
6.5.6. LAMEA MARKET SIZE AND FORECAST, BY LOCATION OF TESTING
CHAPTER 7: COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. COMPANY OVERVIEW
7.1.2. COMPANY SNAPSHOT
7.1.3. OPERATING BUSINESS SEGMENTS
7.1.4. PRODUCT PORTFOLIO
7.1.5. BUSINESS PERFORMANCE
7.1.6. KEY STRATEGIC MOVES AND DEVELOPMENTS
7.2. BECTON DICKINSON COMPANY
7.2.1. COMPANY OVERVIEW
7.2.2. COMPANY SNAPSHOT
7.2.3. OPERATING BUSINESS SEGMENTS
7.2.4. PRODUCT PORTFOLIO
7.2.5. BUSINESS PERFORMANCE
7.2.6. KEY STRATEGIC MOVES AND DEVELOPMENTS
7.3. BIOMÉRIEUX, INC.
7.3.1. COMPANY OVERVIEW
7.3.2. OPERATING BUSINESS SEGMENTS
7.3.3. PRODUCT PORTFOLIO
7.3.4. BUSINESS PERFORMANCE
7.3.5. KEY STRATEGIC MOVES AND DEVELOPMENTS
7.4. BIO-RAD LABORATORIES INC.
7.4.1. COMPANY OVERVIEW
7.4.2. COMPANY SNAPSHOT
7.4.3. OPERATING BUSINESS SEGMENTS
7.4.4. PRODUCT PORTFOLIO
7.4.5. BUSINESS PERFORMANCE
7.4.6. KEY STRATEGIC MOVES AND DEVELOPMENTS
7.5. DANAHER CORPORATION
7.5.1. COMPANY OVERVIEW
7.5.2. COMPANY SNAPSHOT
7.5.3. OPERATING BUSINESS SEGMENTS
7.5.4. PRODUCT PORTFOLIO
7.5.5. BUSINESS PERFORMANCE
7.5.6. KEY STRATEGIC MOVES AND DEVELOPMENTS
7.6. DIASORIN MOLECULAR LLC
7.6.1. COMPANY OVERVIEW
7.6.2. COMPANY SNAPSHOT
7.6.3. OPERATING BUSINESS SEGMENTS
7.6.4. PRODUCT PORTFOLIO
7.6.5. BUSINESS PERFORMANCE
7.6.6. KEY STRATEGIC MOVES AND DEVELOPMENTS
7.7. HOLOGIC INC.
7.7.1. COMPANY OVERVIEW
7.7.2. COMPANY SNAPSHOT
7.7.3. OPERATING BUSINESS SEGMENTS
7.7.4. PRODUCT PORTFOLIO
7.7.5. BUSINESS PERFORMANCE
7.7.6. KEY STRATEGIC MOVES AND DEVELOPMENTS
7.8. ORASURE TECHNOLOGIES, INC.
7.8.1. COMPANY OVERVIEW
7.8.2. OPERATING BUSINESS SEGMENTS
7.8.3. PRODUCT PORTFOLIO
7.8.4. BUSINESS PERFORMANCE
7.8.5. KEY STRATEGIC MOVES AND DEVELOPMENTS
7.9. ROCHE HOLDINGS AG
7.9.1. COMPANY OVERVIEW
7.9.2. COMPANY SNAPSHOT
7.9.3. OPERATING BUSINESS SEGMENTS
7.9.4. PRODUCT PORTFOLIO
7.9.5. BUSINESS PERFORMANCE
7.9.6. KEY STRATEGIC MOVES AND DEVELOPMENTS
7.10. THERMO FISHER SCIENTIFIC (AFFYMETRIX)
7.10.1. COMPANY OVERVIEW
7.10.2. OPERATING BUSINESS SEGMENTS
7.10.3. PRODUCT PORTFOLIO
7.10.4. BUSINESS PERFORMANCE
7.10.5. KEY STRATEGIC MOVES AND DEVELOPMENTS
List of Tables
TABLE 01. STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 (MILLION TESTS)
TABLE 02. STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 03. STD TESTING MARKET FOR CHLAMYDIA, BY REGION, 2020-2030 (MILLION TESTS)
TABLE 04. STD TESTING MARKET FOR CHLAMYDIA, BY REGION, 2020-2030 ($MILLION)
TABLE 05. STD TESTING MARKET FOR GONORRHEA, BY REGION, 2020-2030 (MILLION TESTS)
TABLE 06. STD TESTING MARKET FOR GONORRHEA, BY REGION, 2020-2030 ($MILLION)
TABLE 07. STD TESTING MARKET FOR HERPES SIMPLEX VIRUS, BY REGION, 2020-2030 (MILLION TESTS)
TABLE 08. STD TESTING MARKET FOR HERPES SIMPLEX VIRUS, BY REGION, 2020-2030 ($MILLION)
TABLE 09. STD TESTING MARKET FOR SYPHILIS, BY REGION, 2020-2030 (MILLION TESTS)
TABLE 10. STD TESTING MARKET FOR SYPHILIS, BY REGION, 2020-2030 ($MILLION)
TABLE 11. STD TESTING MARKET FOR HUMAN PAPILOMAVIRUS, BY REGION, 2020-2030 (MILLION TESTS)
TABLE 12. STD TESTING MARKET FOR HUMAN PAPILOMAVIRUS, BY REGION, 2020-2030 ($MILLION)
TABLE 13. STD TESTING MARKET FOR OTHER DISEASES, BY REGION, 2020-2030 (MILLION TESTS)
TABLE 14. STD TESTING MARKET FOR OTHER DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 15. STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 (MILLION TESTS)
TABLE 16. STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 ($MILLION)
TABLE 17. STD TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2020-2030 (MILLION TESTS)
TABLE 18. STD TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2020-2030 ($MILLION)
TABLE 19. STD TESTING MARKET FOR POINT OF CARE TESTING, BY REGION, 2020-2030 (MILLION TESTS)
TABLE 20. STD TESTING MARKET FOR POINT OF CARE TESTING, BY REGION, 2020-2030 ($MILLION)
TABLE 21. GLOBAL STD TESTING MARKET, VOLUME (NO. OF TESTS, MILLION)
TABLE 22. GLOBAL STD TESTING MARKET, VALUE ($ MILLION)
TABLE 23. NORTH AMERICA STD TESTING MARKET, BY COUNTRY, 2020-2030 VOLUME ($MILLION)
TABLE 24. NORTH AMERICA STD TESTING MARKET, BY COUNTRY, 2020-2030 VALUE ($MILLION)
TABLE 25. NORTH AMERICA STD TESTING MARKET, BY DISEASE TYPE, VOLUME 2020-2030 ($MILLION)
TABLE 26. NORTH AMERICA STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VALUE ($MILLION)
TABLE 27. NORTH AMERICA STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VOLUME ($MILLION)
TABLE 28. NORTH AMERICA STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VALUE ($MILLION)
TABLE 29. EUROPE STD TESTING MARKET, BY COUNTRY, 2020-2030 VOLUME ($MILLION)
TABLE 30. EUROPE STD TESTING MARKET, BY COUNTRY, 2020-2030 VALUE ($MILLION)
TABLE 31. EUROPE STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VOLUME ($MILLION)
TABLE 32. EUROPE STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VALUE ($MILLION)
TABLE 33. EUROPE STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VOLUME ($MILLION)
TABLE 34. EUROPE STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VALUE ($MILLION)
TABLE 35. ASIA-PACIFIC STD TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 36. ASIA-PACIFIC STD TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 37. ASIA-PACIFIC STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VOLUME ($MILLION)
TABLE 38. ASIA-PACIFIC STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VALUE ($MILLION)
TABLE 39. ASIA-PACIFIC STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VOLUME ($MILLION)
TABLE 40. ASIA-PACIFIC STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VALUE ($MILLION)
TABLE 41. LAMEA STD TESTING MARKET, BY COUNTRY, 2020-2030 VOLUME ($MILLION)
TABLE 42. LAMEA STD TESTING MARKET, BY COUNTRY, 2020-2030 VALUE ($MILLION)
TABLE 43. LAMEA STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VOLUME ($MILLION)
TABLE 44. LAMEA STD TESTING MARKET, BY DISEASE TYPE, 2020-2030 VALUE ($MILLION)
TABLE 45. LAMEA STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VOLUME ($MILLION)
TABLE 46. LAMEA STD TESTING MARKET, BY LOCATION OF TESTING, 2020-2030 VALUE ($MILLION)
TABLE 47. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 48. ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 49. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 50. BD: COMPANY SNAPSHOT
TABLE 51. BD: PRODUCT SEGMENTS
TABLE 52. BECTON DICKINSON COMPANY: PRODUCT PORTFOLIO
TABLE 53. BIOMERIEUX: COMPANY SNAPSHOT
TABLE 54. BIOMERIEUX: OPERATING SEGMENTS
TABLE 55. BIOMERIEUX: PRODUCT PORTFOLIO
TABLE 56. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT
TABLE 57. BIO-RAD LABORATORIES INC.: OPERATING SEGMENTS
TABLE 58. BIO-RAD LABORATORIES INC.: PRODUCT PORTFOLIO
TABLE 59. DANAHER: COMPANY SNAPSHOT
TABLE 60. DANAHER: OPERATING SEGMENTS
TABLE 61. DANAHER: PRODUCT PORTFOLIO
TABLE 62. DIASORIN: COMPANY SNAPSHOT
TABLE 63. DIASORIN: OPERATING SEGMENTS
TABLE 64. DIASORIN: PRODUCT PORTFOLIO
TABLE 65. HOLOGIC INC.: COMPANY SNAPSHOT
TABLE 66. HOLOGIC: OPERATING SEGMENTS
TABLE 67. HOLOGIC: PRODUCT PORTFOLIO
TABLE 68. ORASURE: COMPANY SNAPSHOT
TABLE 69. ORASURE: OPERATING SEGMENTS
TABLE 70. ORASURE: PRODUCT PORTFOLIO
TABLE 71. ROCHE: COMPANY SNAPSHOT
TABLE 72. ROCHE: OPERATING SEGMENTS
TABLE 73. ROCHE: PRODUCT PORTFOLIO
TABLE 74. THERMO FISHER SCIENTIFIC (AFFYMETRIX): COMPANY SNAPSHOT
TABLE 75. THERMO FISHER SCIENTIFIC (AFFYMETRIX): OPERATING SEGMENTS
TABLE 76. THERMO FISHER SCIENTIFIC (AFFYMETRIX): PRODUCT PORTFOLIO
List of Figures
FIGURE 01. STD TESTING MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2020
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. HIGH INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. U.S. STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 14. CANADA STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 15. MEXICO STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 16. GERMANY STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 17. FRANCE STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 18. UK STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 19. ITALY STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 20. REST OF EUROPE STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 21. JAPAN STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 22. CHINA STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 23. INDIA STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 24. REST OF ASIA-PACIFIC STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 25. LATIN AMERICA STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 26. MIDDLE EAST AND AFRICA STD TESTING MARKET, 2020 & 2030 VOLUME AND VALUE ($MILLION)
FIGURE 27. ABBOTT LABORATORIES: NET SALES, 2018-2020 ($MILLION)
FIGURE 28. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2020(%)
FIGURE 30. BECTON DICKINSON COMPANY: NET SALES, 2018-2020 ($MILLION)
FIGURE 31. BD COMPANY: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32. BD COMPANY: REVENUE SHARE BY REGION, 2020(%)
FIGURE 33. BIOMERIEUX: NET SALES, 2018-2020 ($MILLION)
FIGURE 34. BIOMERIEUX: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35. BIOMERIEUX: REVENUE SHARE BY REGION, 2020(%)
FIGURE 36. BIO-RAD LABORATORIES INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 37. BIO-RAD LABORATORIES INC.: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 38. BIO-RAD LABORATORIES INC.: REVENUE SHARE BY REGION, 2020(%)
FIGURE 39. DANAHER: NET SALES, 2018-2020 ($MILLION)
FIGURE 40. DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41. DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 42. DIASORIN: NET SALES, 2018-2020 ($MILLION)
FIGURE 43. DIASORIN: REVENUE SHARE BY SEGMENT/TECHNOLOGY, 2020 (%)
FIGURE 44. DIASORIN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45. HOLOGIC: NET SALES, 2018-2020 ($MILLION)
FIGURE 46. HOLOGIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 47. HOLOGIC: REVENUE SHARE BY REGION, 2020(%)
FIGURE 48. ORASURE: NET SALES, 2018-2020 ($MILLION)
FIGURE 49. ORASURE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 50. ORASURE TECHNOLOGIES, INC.: REVENUE SHARE BY REGION, 2020(%)
FIGURE 51. ROCHE: NET SALES, 2018-2020 ($MILLION)
FIGURE 52. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 53. THERMO FISHER: NET SALES, 2018-2020 ($MILLION)
FIGURE 54. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 55. THERMO FISHER: REVENUE SHARE BY REGION, 2020 (%)

Companies Mentioned

  • Abbott laboratories
  • Becton Dickinson Company
  • BioMérieux Inc.
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • Diasorin Molecular LLC
  • Hologic IncOrasure Technologies Inc.
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...